SZD.F Santen Pharmaceutical Co. Ltd
- Market cap
- EUR 3.57B
- P/E
- 16.8x
- P/B
- 2.06x
- ROE
- 10.2%
- Dividend yield
- 2.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is SZD.F undervalued?
Graham numberSZD.F trades 24.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Santen Pharmaceutical Co. Ltd fundamental analysis
No fundamental analysis for Santen Pharmaceutical Co. Ltd yet.
Santen Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocula…
Full company profileSanten Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Santen Pharmaceutical Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 199B | 225B | 234B | 242B | 250B | 266B | 279B | 302B | 300B | 292B | 287B |
| Gross Profit | 124B | 139B | 143B | 147B | 151B | 157B | 166B | 179B | 171B | 170B | 165B |
| Operating Income | 32.5B | 38.7B | 45.1B | 33.5B | 12.9B | 35.9B | -3.09B | 38.5B | 46.9B | 47.8B | 38.8B |
| EBITDA | - | 50.6B | 57.0B | 51.1B | 30.7B | 53.9B | 12.9B | 50.7B | 59.0B | 58.2B | 59.8B |
| Net Income | 23.1B | 35.3B | 31.9B | 23.6B | 6.83B | 27.2B | -14.9B | 26.6B | 36.3B | 37.4B | 30.9B |
| EPS | 57 | 87 | 80 | 59 | 17 | 68 | -40 | 73 | 106 | 116 | 96 |
| Balance Sheet | |||||||||||
| Total Assets | 323B | 388B | 391B | 409B | 402B | 460B | 421B | 436B | 409B | 423B | 418B |
| Total Liabilities | 68.9B | 101B | 98.6B | 106B | 95.3B | 123B | 128B | 130B | 124B | 127B | 115B |
| Shareholders' Equity | 253B | 286B | 291B | 303B | 308B | 337B | 294B | 306B | 286B | 297B | 304B |
| Cash & Short-term Investments | 53.3B | 69.3B | 70.8B | 91.4B | 62.9B | 83.0B | 57.9B | 94.6B | 93.0B | 80.9B | 81.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.8B | 42.8B | 32.9B | 39.9B | 38.8B | 46.0B | 37.1B | 72.6B | - | - | 39.4B |
| Capital Expenditure | 4.15B | 3.98B | 5.47B | 5.82B | 4.14B | 17.3B | 24.6B | 10.7B | 0.00 | 0.00 | 17.6B |
| Free Cash Flow | - | 32.9B | 24.6B | 30.7B | 15.0B | 10.2B | 12.6B | 62.0B | - | - | 21.8B |
| Ratios | |||||||||||
| ROE | 9.1% | 12.3% | 11.0% | 7.8% | 2.2% | 8.1% | -5.1% | 8.7% | 12.7% | 12.6% | 10.2% |
| ROA | 7.1% | 9.1% | 8.2% | 5.8% | 1.7% | 5.9% | -3.5% | 6.1% | 8.9% | 8.8% | 7.4% |
| Net Profit Margin | 11.6% | 15.7% | 13.6% | 9.8% | 2.7% | 10.2% | -5.4% | 8.8% | 12.1% | 12.8% | 10.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Santen Pharmaceutical Co. Ltd dividends
- Dividend yield
- 2.12%
- Forward dividend
- 0.24 EUR
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | JPY 11.9B | 33 | 44.6% |
| 2023 | JPY 12.6B | 34 | - |
| 2022 | JPY 12.0B | 30 | 44.1% |
| 2021 | JPY 11.2B | 28 | 163.8% |
| 2020 | JPY 10.4B | 26 | 43.9% |
| 2019 | JPY 10.6B | 27 | 33.1% |
| 2018 | JPY 10.6B | 26 | 29.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Mar 27, 2015.
Who owns Santen Pharmaceutical Co. Ltd
- Insiders 2.93%
- Institutions 50.63%
- Public & others 46.44%
- Shares outstanding 322M
- Free float 315M
Santen Pharmaceutical Co. Ltd company profile
- Company name
- Santen Pharmaceutical Co. Ltd
- Ticker
- SZD.F
- ISIN
- JP3336000009
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,968
- Fiscal year end
- March
- Address
- Grand Front Osaka Tower A, Kita, Japan, 530-8552
- Phone
- 81 6 7664 8621
- Website
- santen.com/en
About Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; cepetaprost, an FP/EP3 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; latanoprost, a prostaglandin Fa derivative emulsified eye drops; netalusdil mesylate, a ROCK/NET inhibitor; Netalus, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative; netalusdyl mesialate/latanoprost, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative that is in phase I clinical trial for the treatment of glaucoma and ocular hypertension area. The company also provides cyclosporine, which is used for vernal catarrhal infections; olodaterol hydrochloride, used for dry eye that is in late-stage Phase 11 trial for the treatment of Keroconjunctival disease; olodaterol hydrochloride, used for allergic conjunctivitis that is in the Phase I/Early Phase II trial for the treatment of Keroconjunctival disease; epinastine hydrochloride, an eyelid cream formulation for allergic conjunctivitis; epinastine, a high-dose eye drop formulation for allergic conjunctivitis; nintedanib, a drug targeting pterygium that is in late-stage Phase II trial for the treatment of Keroconjunctival disease; and eflimrufuspalfa, which is used for diabetic macular edema. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Kita, Japan.
Santen Pharmaceutical Co. Ltd management
10- Mr. Takeshi ItoPresident, CEO & Representative Director · born 1959
- Ms. Rie NakajimaCOO & Director · born 1977
- Mr. Kazuo KoshijiCFO & Corporate Officer
- Mr. Daisuke NakataChief Digital & Information Officer
- Ms. Kaori ItagakiGeneral Manager of Investor Relations Group
- Ms. Mika MasunariCorporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer
- Ms. Marianthi PsachaCorporate Officer, Head of EMEA Business and International Pricing Market Access & Public Affairs
- Mr. Shinichi TeramachiCorp. Officer, Head of Sales and Head of Japan Sales & Marketing
- Ms. Yoko SaikiCorporate Officer & Chief Human Resources Officer
- Mr. Kenji MorishimaCorporate Officer & Head of China Product Development Department